Im Ellie Eunkyung 4
4 · CRESCENT BIOPHARMA, INC. · Filed Jun 23, 2026
Research Summary
AI-generated summary of this filing
Crescent BioPharma (CBIO) CMO Im Ellie Eunkyung Sells 1,219 Shares
What Happened
Im Ellie Eunkyung, Chief Medical Officer of Crescent BioPharma (CBIO), sold 1,219 shares on June 22, 2026, for a weighted average price of $17.99, resulting in proceeds of approximately $21,930. This was a sale (not a purchase) and was made to satisfy tax withholding related to vested restricted stock units.
Key Details
- Transaction date: 2026-06-22 (Form 4 filed 2026-06-23; appears timely).
- Transaction type: Sale (code S).
- Shares sold: 1,219; weighted average price reported $17.99; total proceeds ≈ $21,930.
- Price range: sales occurred at prices between $16.88 and $18.86 (multiple transactions); the filing notes the weighted average and offers to provide per-price breakdown on request.
- Reason/footnotes: Shares were automatically sold to satisfy tax withholding on RSUs granted Dec 15, 2025; sales were effected pursuant to a Rule 10b5-1 plan adopted Feb 25, 2026.
- Shares owned after transaction: Not disclosed in this filing.
Context
Sales to cover tax withholding on vested awards are routine and do not necessarily signal a change in insider sentiment. The use of a Rule 10b5-1 plan indicates the trades were pre-planned to meet tax obligations.
Insider Transaction Report
Form 4
Im Ellie Eunkyung
Chief Medical Officer
Transactions
- Sale
Ordinary Shares
[F1][F2]2026-06-22$17.99/sh−1,219$21,930→ 22,069 total
Footnotes (2)
- [F1]Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Signature
/s/ Barbara Bispham, as attorney-in-fact for Ellie Im|2026-06-23